Charles River Labs executive sells 5,046 shares

Q: How many CHARLES RIVER LABORATORIES (CRL) shares did Shannon M. Parisotto sell?

Shannon M. Parisotto sold 5,046 shares of CHARLES RIVER LABORATORIES (CRL) common stock on August 5, 2026, at $263.00 per share. This transaction was reported as a sale of non-derivative common stock on a Form 4 filing.

Q: What indirect CRL shareholdings does Shannon M. Parisotto report on this Form 4?

In addition to direct holdings, the Form 4 reports 9,680 shares held “By Trust” and 28,510 shares held “by Karpathos Investments LLC”. Both positions are classified as indirect ownership of CHARLES RIVER LABORATORIES (CRL) common stock.

Q: Was the CRL stock sale by Shannon M. Parisotto made under a Rule 10b5-1 plan?

Yes. The Form 4 footnote states the sale occurred under a Rule 10b5-1 Trading Plan initially adopted on March 4, 2026. The filing’s Rule 10b5-1 checkbox is also affirmed as true for this transaction.

Q: What type of security was involved in Shannon M. Parisotto’s CRL transaction?

The transaction involved Common Stock of CHARLES RIVER LABORATORIES (CRL). It is categorized as a non-derivative security, with the sale of 5,046 shares at a reported price of $263.00 per share.

Accepted by SEC EDGAR 08/06/2026 - 04:49 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Charles River Laboratories International, Inc. executive Shannon M. Parisotto, CEVP of Discovery & Safety Assessment, reported a sale of 5,046 shares of common stock at $263.00 per share on August 5, 2026, under a Rule 10b5-1 Trading Plan initially adopted on March 4, 2026. Following the sale, Parisotto directly holds 4,807 shares, and also reports indirect ownership of 9,680 shares held by a trust and 28,510 shares held through Karpathos Investments LLC.

Insider Trade Summary 10b5-1

Net Seller: 5,046 shares

Net Sell 1 txn

Insider Parisotto Shannon M

Role CEVP, Disc & Safety Assessment

Sold 5,046 shs ($1.33M)

Type	Security	Shares	Price	Value
Sale	Common Stock ^F1	5,046	$263.00	$1.33M
Holding	Common Stock	--	--	--
Holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 4,807 shares (Direct); Common Stock — 9,680 shares (Indirect, By Trust); Common Stock — 28,510 shares (Indirect, by Karpathos Investments LLC)

Footnotes (1)

F1. This sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 4, 2026.

Key Figures

Shares Sold: 5,046 shares Sale Price: $263.00 per share Direct Holdings After Sale: 4,807 shares +3 more

6 metrics

Shares Sold 5,046 shares Common Stock sale on August 5, 2026

Sale Price $263.00 per share Price for the 5,046 Common Stock shares sold

Direct Holdings After Sale 4,807 shares Total direct Common Stock shares following the transaction

Indirect Holdings by Trust 9,680 shares Indirect Common Stock ownership classified as “By Trust”

Indirect Holdings via Karpathos Investments LLC 28,510 shares Indirect Common Stock ownership “by Karpathos Investments LLC”

Rule 10b5-1 Plan Adoption Date March 4, 2026 Trading plan under which the reported sale occurred

Key Terms

Rule 10b5-1 Trading Plan, indirect ownership, By Trust, Sale in open market or private transaction

4 terms

Rule 10b5-1 Trading Plan regulatory

"This sale occurred pursuant to a Rule 10b5-1 Trading Plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

indirect ownership financial

"classified as indirect ownership with nature of ownership By Trust"

By Trust financial

"total_shares_following_transaction 9680.0000, nature_of_ownership By Trust"

Sale in open market or private transaction financial

"transaction_code_description Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CHARLES RIVER LABORATORIES (CRL) shares did Shannon M. Parisotto sell?

Shannon M. Parisotto sold 5,046 shares of CHARLES RIVER LABORATORIES (CRL) common stock on August 5, 2026, at $263.00 per share. This transaction was reported as a sale of non-derivative common stock on a Form 4 filing.

What are Shannon M. Parisotto’s remaining direct CRL holdings after this Form 4?

After the reported sale, Shannon M. Parisotto directly holds 4,807 shares of CHARLES RIVER LABORATORIES (CRL) common stock. This figure reflects the total direct shares following the transaction reported in the Form 4 filing.

What indirect CRL shareholdings does Shannon M. Parisotto report on this Form 4?

In addition to direct holdings, the Form 4 reports 9,680 shares held “By Trust” and 28,510 shares held “by Karpathos Investments LLC”. Both positions are classified as indirect ownership of CHARLES RIVER LABORATORIES (CRL) common stock.

Was the CRL stock sale by Shannon M. Parisotto made under a Rule 10b5-1 plan?

Yes. The Form 4 footnote states the sale occurred under a Rule 10b5-1 Trading Plan initially adopted on March 4, 2026. The filing’s Rule 10b5-1 checkbox is also affirmed as true for this transaction.

What role does Shannon M. Parisotto hold at CHARLES RIVER LABORATORIES (CRL)?

Shannon M. Parisotto is an officer of CHARLES RIVER LABORATORIES (CRL) with the title CEVP, Discovery & Safety Assessment. The reported Form 4 transaction involves common stock associated with this executive role.

What type of security was involved in Shannon M. Parisotto’s CRL transaction?

The transaction involved Common Stock of CHARLES RIVER LABORATORIES (CRL). It is categorized as a non-derivative security, with the sale of 5,046 shares at a reported price of $263.00 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parisotto Shannon M

(Last)

(First)

(Middle)

C/O CHARLES RIVER LABORATORIES

251 BALLARDVALE STREET

(Street)

WILMINGTON

MASSACHUSETTS

01887

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CEVP, Disc & Safety Assessment

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/05/2026		S		5,046⁽¹⁾	D	$263	4,807	D
Common Stock								9,680	I	By Trust
Common Stock								28,510	I	by Karpathos Investments LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 4, 2026.

	/s/ Shannon M. Parisotto	08/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR